| Literature DB >> 21738475 |
Francesco Renzi1, Pablo Manfredi, Manuela Mally, Suzette Moes, Paul Jenö, Guy R Cornelis.
Abstract
C. canimorsus 5 has the capacity to grow at the expenses of glycan moieties from host cells N-glycoproteins. Here, we show that C. canimorsus 5 also has the capacity to deglycosylate human IgG and we analyze the deglycosylation mechanism. We show that deglycosylation is achieved by a large complex spanning the outer membrane and consisting of the Gpd proteins and sialidase SiaC. GpdD, -G, -E and -F are surface-exposed outer membrane lipoproteins. GpdDEF could contribute to the binding of glycoproteins at the bacterial surface while GpdG is a endo-β-N-acetylglucosaminidase cleaving the N-linked oligosaccharide after the first N-linked GlcNAc residue. GpdC, resembling a TonB-dependent OM transporter is presumed to import the oligosaccharide into the periplasm after its cleavage from the glycoprotein. The terminal sialic acid residue of the oligosaccharide is then removed by SiaC, a periplasm-exposed lipoprotein in direct contact with GpdC. Finally, most likely degradation of the oligosaccharide proceeds sequentially from the desialylated non reducing end by the action of periplasmic exoglycosidases, including β-galactosidases, β-N-Acetylhexosaminidases and α-mannosidases.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21738475 PMCID: PMC3128124 DOI: 10.1371/journal.ppat.1002118
Source DB: PubMed Journal: PLoS Pathog ISSN: 1553-7366 Impact factor: 6.823
Figure 1Genetic analysis of the PUL5 locus.
(A). Schematic representation of the PUL5 putative operon (top: new gene designation; below: gene codes derived from the annotation of the genome (Manfredi et al. submitted). (B). Growth of the various individual gpd knockout (black) and complemented (grey) mutants on HEK293 cells (moi = 0.2; 23 hours growth). (C). Glycosylation state of fetuin samples incubated for 2 hours in the presence of the different strains, monitored by staining with SNA that recognizes terminal sialic acid (2–6) linked to Gal or to GalNAc. (D). Western blot analysis with anti-fetuin antibodies of fetuin samples incubated as in (C).
Figure 2LC-MS analysis reveals an endo-β-N-acetylglucosaminidase activity of GpdG.
Glycosylation analysis of fetal calf serum fetuin. (A) N156 glycosylation of untreated bovine fetuin. Selected ion chromatogram for the quadruply charged tryptic peptide whose m/z is in accordance with a GlcNAc5Man3Gal3Sial3 glycosyl moiety on the LCPDCPLLAPLNDSR peptide. The inset shows the isotope pattern for the N156 glycopeptide. The blue squares represent GlcNAc, the red and green circles Man and Gal, respectively, and the orange diamonds Sial. (B) Selected ion chromatogram for the doubly charged N156 GlcNAc-modified LCPDCPLLAPLNDSR glycopeptide of fetuin that had been incubated with wild-type Cc5. The sugar moieties are designated as in (A). (C) Fragmentation spectrum of the N156- GlcNAc species with the y- and b-ions that conclusively show the GlcNAc modification of N156. (D) N156 glycosylation of bovine fetuin that had been treated with the ΔgpdG strain. Selected ion chromatogram for the quadruply charged tryptic peptide carrying the presumed GlcNAc5Man3Gal3Sial3 glycosyl moiety on the LCPDCPLLAPLNDSR peptide. The inset shows the isotope pattern for the N156 glycopeptide. The sugar moieties are designated as in (A).
Figure 3The F197DGFDIDWE205 chitinase motif of GpdG is the catalytic site.
E205 from GpdG was substituted with a glycine. (A): Number of divisions after 23 h growth on HEK293 cells of the ΔgpdG mutant complemented with gpdG* encoding the catalytic mutant. (B): Fetuin glycosylation state of samples incubated for 3 hours in the presence of the different strains, determined by staining with the Sambucus nigra lectin (SNA) that recognizes terminal sialic acid (2–6) linked to Gal or to GalNAc. (C): same as B after western blot analysis with anti-fetuin antibodies.
Figure 4Human IgG deglycosylation.
Glycosylation state of human IgG samples incubated for 3 hours in the presence of wt and ΔgpdG bacteria monitored by Coomassie staining (A), western blot analysis with anti-IgG antibodies (B) and staining with SNA (C).
Figure 5LC-MS analysis of IgG.
Glycosylation analysis of human IgG. (A) N297 glycosylation of untreated human IgG. Selected ion chromatogram for the triply charged tryptic peptide whose m/z is in accordance with a GlcNAc4Man3Fuc1Gal2Sial1 glycosyl moiety on the EEQYNSTYR peptide. The inset shows the isotope pattern for the N297 glycopeptide. The blue squares represent GlcNAc, the red and green circles Man and Gal, respectively, the orange diamonds Sial, and triangle Fuc. (B) N297 glycosylation of untreated human IgG. Selected ion chromatogram for the triply charged tryptic peptide whose m/z is in accordance with the GlcNAc4Man3Fuc1Gal2 glycosyl moiety on the EEQYNSTYR peptide. The inset shows the isotope pattern for the N297 glycopeptide. The sugar moieties are designated as in (A). (C) Selected ion chromatogram for the doubly charged N297 GlcNAc1Fuc1-modified glycopeptide of IgG that had been incubated with wild-type Cc5. The sugar moieties are designated as in (A). (D) Fragmentation spectrum of the N297 GlcNAc1Fuc1 species with the y- and b-ions that conclusively show the GlcNAc1Fuc1 modification of N297. (E) N297 glycosylation of human IgG that had been treated with the ΔgpdG strain: selected ion chromatogram for the triply charged tryptic peptide carrying the presumed GlcNAc4Man3Fuc1Gal2Sial1 glycosyl moiety on the EEQYNSTYR peptide. The inset shows the isotope pattern for the N297 glycopeptide. For the sugar structure see (A). (F) N297 glycosylation of human IgG that had been treated with the ΔgpdG strain: selected ion chromatogram for the triply charged tryptic peptide carrying the presumed GlcNAc4Man3Fuc1Gal2 glycosyl moiety on the EEQYNSTYR peptide. The inset shows the isotope pattern for the N297 glycopeptide. For the sugar structure see (A).
Figure 6Lipid modification of GpdD and GpdG is essential for their activity.
(A) Number of divisions after 23 h growth on HEK293 cells of the ΔgpdG bacteria complemented with gpdD and gpdG. (B) Fetuin glycosylation state of samples incubated for 2 hours in the presence of the different strains, determined by staining with SNA. (C) Same as B analyzed by western blot with anti-fetuin antibodies.
Figure 7Gpd proteins form a complex with sialidase.
Streptavidine affinity purification of GpdC-His-Strep expressed from its natural promoter in a ΔgpdC background. (A) Detection by western blot of GpdC (anti-His antibody), GpdG (anti-GpdG) and Sialidase (anti-SiaC) in the elution fractions. (B) List of protein identified by Mass spectrometry in the elution fractions.
Figure 8Sialidase localization and interaction with GpdC.
(A) Autoradiography of 3H-palmitate labeled sialidase in different bacteria. (B) Detection of sialidase by western blot analysis (anti-SiaC antibody) in total cell extracts (TC) and outer membrane protein (OMP) fractions of Cc5 wt and ΔsiaC bacteria complemented with the soluble periplasmic sialidase (SiaCC17Y). (C) Number of divisions after 23 hours growth on HEK293 cells of ΔsiaC bacteria expressing SiaC or SiaCC17Y. (D) Fetuin glycosylation state after 2 hours of incubation in the presence of the different strains, determined by staining SNA. (E) Same as D, analyzed by western blot with anti-fetuin antibodies. (F) Co-purification of SiaC with GpdC-Strep-His produced in a ΔgpdCDGE background. GpdC was detected with anti-Strep antibody and SiaC with anti-SiaC antibodies.
Figure 9Functional model of complex N-linked glycan moieties deglycosylation processing by C. canimorsus.
Individual glycan processing steps are illustrated. (A) The glycan moiety is bound at the bacterial surface by the Gpd complex. (B) The glycan mopiety is endo-cleaved by GpdG and imported into the periplasm trough the GpdC pore. (C) Terminal sialic acid is cleaved by sialidase (SiaC). (D) The glycan is further processed by the sequencial activity of several periplasmic exoglycosidases.
Bacterial strains used in this study.
| Bacterial strains | Description or genotype | Reference or source |
|
| ||
| S17-1 |
|
|
|
| ||
|
| Human fatal septicemia after dog bite 1995 |
|
|
| Replacement of |
|
|
| Replacement of | Manfredi |
|
| Replacement of | This study |
|
| Replacement of | This study |
|
| Replacement of | This study |
|
| Replacement of | This study |
|
| Replacement of | This study |
Oligonucleotides used in this study.
| Ref. | Name | Sequence 5′-3′ | Restriction | Gene | PCR |
| 5502 | ermF-fw |
|
| ||
| 5503 | ermF-rev |
|
| ||
| 5081 | PgpdC-fw |
| SalI | ||
| 5469 | PgpdC-rev |
| NcoI | ||
| 5082 | gpdC-rev |
| SpeI |
| |
| 5467 | gpdC-His-rev |
| SpeI |
| |
| 5530 | gpdC-Strep-rev |
| SpeI |
| |
| 5001 | gpdGKO-1.1-fw |
| PstI |
| A |
| 5002 | gpdGKO-1.2-rev |
|
| B | |
| 5005 | gpdGKO-2.1-fw |
|
| C | |
| 5006 | gpdGKO-2.2-rev |
| SpeI |
| D |
| 4850 | gpdDKO-1.1-fw |
| PstI |
| A |
| 4851 | gpdDKO-1.2-rev |
|
| B | |
| 4854 | gpdDKO-2.1-fw |
|
| C | |
| 4855 | gpdDKO-2.2-rev |
| SpeI |
| D |
| 5073 | gpdCKO-1.1-fw |
| PstI |
| A |
| 5074 | gpdCKO-1.2-rev |
|
| B | |
| 5075 | gpdCKO-2.1-fw |
|
| C | |
| 5083 | gpdCKO-2.2-rev |
| SpeI |
| D |
| 5951 | gpdEKO-1.1-fw |
| PstI |
| A |
| 5952 | gpdEKO-1.2-rev |
|
| B | |
| 5953 | gpdEKO-2.1-fw |
|
| C | |
| 5954 | gpdEKO-2.2-rev |
| SpeI |
| D |
| 5955 | gpdFKO-1.1-fw |
| PstI |
| A |
| 5956 | gpdFKO-1.2-rev |
|
| B | |
| 5957 | gpdFKO-2.1-fw |
|
| C | |
| 5958 | gpdFKO-2.2-rev |
| SpeI |
| D |
| 6133 | gpdD-fw |
| NcoI |
| |
| 6057 | gpdD-rev |
| XbaI |
| |
| 5008 | gpdG-fw |
| NcoI |
| |
| 6055 | gpdG-rev |
| XbaI |
| |
| 5959 | gpdE-fw |
| NcoI |
| |
| 5960 | gpdE-rev |
| XbaI |
| |
| 5962 | gpdF-fw |
| NcoI |
| |
| 5963 | gpdF-rev |
| XbaI |
| |
| 6056 | gpdDCys-fw |
| NcoI |
| |
| 6054 | gpdGCys-fw |
| NcoI |
| |
| 6060 | gpdG-E/G-fw |
|
| ||
| 6061 | gpdG-E/G-rev |
|
| ||
| 5045 | siaCCys-fw |
|
| ||
| 5046 | siaCCys-rev |
|
|
Plasmids used in this study.
| Plasmid | Description | Reference or source |
| pMM47.A |
|
|
| pPM1 | pMM47.A where the | This study |
| pPM2 | Full length | This study |
| pPM3 | Full length | This study |
| pFR4 | Full length | This study |
| pFR5 | Full length | This study |
| pFR6 | Full length | This study |
| pFR7 | Full length | This study |
| pFR8 | Full length | This study |
| pFR9 | Full length | This study |
| pFR10 | Full length | This study |
| pMM121.1 | Full length | This study |
| pMM25 |
|
|
| pMM52 | Full length |
|
| pMM106 |
|
|